Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1004 participants.
Also called NCT01659580
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,004 participants
- Sponsor
- Tasly Pharmaceuticals, Inc.
- Registry
-
NCT01659580
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Belarus, Canada, Georgia, Mexico, Russia, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01659580. Randomized; quadruple masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2016-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina
- Acronym
- CAESA
- Condition
- Angina Pectoris
- Intervention (Drug)
- T89 high dose
- Intervention (Drug)
- T89 Low dose
- Intervention (Drug)
- Sanqi+Bingpian
- Intervention (Drug)
- Placebo
- Lead sponsor
- Tasly Pharmaceuticals, Inc.
Record details
- Record id
cardio:ct-nct01659580- Content hash
d56af27b0c5fe9839fbd44e38535f5a5d05a460ae8c5d6526f9fa84ebaeb08b8